Navigation Links
The Biotechnology Industry Organization and Critical Path Institute Partner With Mediaplanet, Biocom, and the University of California Office to Spotlight the Science That Is Healing, Fueling and Feeding Our Global Population
Date:12/9/2010

LOS ANGELES, Dec. 9, 2010 /PRNewswire/ -- On Thursday, December 9th, Mediaplanet published one of the largest consumer reports on biotechnology, spearheading an industry-wide call to action advocating consumer support of biotechnology, the science that is helping us confront society's most pressing challenges. By teaming up with the world's largest biotechnology organization, Mediaplanet's 'Biotechnology' encourages appropriate policy action and investment in the science that is healing, fueling and feeding our future. Biotechnology is the medical discovery that saves millions of lives, the agricultural innovation that fends off impending world hunger and the solution to ever-rising crude oil prices. The crucial idea—that investment in biotechnology is an investment in our future and in essence, in ourselves—is the idea this report aims to bring home.

(Logo:  http://photos.prnewswire.com/prnh/20100820/CG52983LOGO)

Rolf Benirschke Dedicates Life After Ulcerative Colitis to Biomedical Advancements

"I've been a beneficiary of modern science based on research," explains former San Diego Charger and NFL Great, Rolf Benirschke, on his struggle with ulcerative colitis, and the blood transfusion that both saved his life and gave him Hepatitis C. Son of a world-renowned pathologist, Benirschke finds himself in the medical field dealing with biotechnology advancements on a daily basis.

No on Proposition 23: California Biofuels Industry Poised for Growth

During the November elections, Proposition 23 was defeated by California voters—California is poised to take the lead in clean and renewable energy, with emerging solutions like algae based biofuels, and large-scale production of advanced biofuels.

James C. Greenwood Explains Regulatory Approval Process for Biosimilars

An important provision of healthcare reform established a regulatory approval process for biosimilars, medicines that are similar to pioneering biologics. BIO encourages the FDA to make patient safety the priority, while preserving necessary incentives to develop new breakthrough therapies.

Mediaplanet's Report:

With the help of the Biotechnology Industry Organization, Critical Path Institute, Biocom, the University of California Office of the President, Algenol, Amgen, Byogy, EquipNet, and Syngenta, Mediaplanet published one of the largest distributed Biotechnology report in US history.

To view this report CLICK HERE or click the link below: http://www.latimesinteractive.com/advertising/mediaplanet/biotechnology/images/LaT%20Biotechnology%20FINAL%20smO.PDF

Mediaplanet creates focused reports on business, healthcare and technology.

For more information go to www.mediaplanet.com or call 312-337-4000.


'/>"/>
SOURCE Mediaplanet
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
2. Yongye Biotechnology International Retains CCG Investor Relations
3. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
4. Yongye Biotechnology International Announces Second Quarter Results
5. BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
6. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
7. DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products
8. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
10. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
11. InNexus Biotechnology Strengthens Patent Team With New Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 2, 2016 Amgen (NASDAQ: ... ) today announced the submission of a Marketing Authorization Application ... a biosimilar candidate to Avastin ® (bevacizumab). The companies ... to the EMA. "The submission of ABP ... seeks to expand our oncology portfolio," said Sean E. ...
(Date:12/2/2016)... ... , ... ACEA Biosciences, Inc. announced today that it will be presenting updated ... World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th. ... for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR T790M ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... (CSS) and the popularity of US Single Day Events (SDE) to organize a ... Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and life sciences industry ...
(Date:12/2/2016)... IL (PRWEB) , ... December 01, 2016 , ... ... to congratulate long-term client Nanowear on their recent FDA Class II 510(k) clearance ... cleared a significant hurdle in commercializing remote cardiac monitoring devices that rely on ...
Breaking Biology Technology:
(Date:11/22/2016)... Minn. , Nov. 22, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... Medical LiveWire Healthcare and Life Sciences Awards ... award caps off an unprecedented year of recognition and ... trials for over 15 years. iMedNet ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is ... analysis for Private Biobanks shows the highest Compounded Annual Growth ... region during the analysis period 2014-2020. ... CAGR of 9.95% followed by Europe ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
Breaking Biology News(10 mins):